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Systemic amyloidosis isa serious clinical disorder for which there isno effective
treatment (1). It is characterized by the widespread extracellular deposition of
autologous protein in an insoluble fibrillar form (2, 3) . The deposits relentlessly
accumulate and persist in the tissues, usually resulting in organ dysfunction and
death within 1-5 yr of diagnosis . The presence of amyloidcan only be confirmed
by histological examination of tissue obtained by biopsy or surgical resection .
These procedures cannot provide information on the presence and distribution
of amyloid in the body as a whole, and in consequence, little is known about the
natural history of this condition .
A wide variety of precursor proteins can form amyloid fibrils, notably Ig light
chains in amyloid of Ig light chain type, amyloid A protein (AA)' in reactive
systemic amyloid, and prealbumin in familial amyloid polyneuropathy and senile
systemic amyloid (1-3) . In addition, a nonfibrillar glycoprotein, amyloid P
component, is present as a minor constituent in all forms of amyloid deposit (4,
5), with the single exception of the intracortical plaques of Alzheimer's disease
and senile dementia of Alzheimer type (6-8). We have previously demonstrated
that amyloid P component is derived from the normal plasma protein, serum
amyloid P component (SAP) (9) . SAP, together with C-reactive protein (CRP),
the classical acute-phase reactant, is a member of the pentraxin family of plasma
proteins, so named because of their molecular appearance as pentameric discs in
the electron microscope (10, 11) . SAP undergoes calcium-dependent binding to
amyloid fibrils in vitro (12) and presumably this is the mechanism by which
plasma SAP that has left the circulation deposits with amyloid fibrils in vivo (9) .
We now report the use of isolated purified SAP as a specific in vivo targeting
vehicle for amyloid . These studies used radiolabeled protein andgamma camera
imaging in mice with experimental amyloidosis, but they establish the important
principle of the use of this approach which has implications for diagnosis and,
perhaps, ultimately treatment of human amyloidosis .
This work was supported in part by Medical Research Council Programme Grant G979/51 to M. B.
Pepys . P . N. Hawkin s is a Medical Research Council Training Fellow .
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Materials and Methods
Mice.
￿
Female CBA/Ca mice, 8-20 wk old, were obtained from the National Institute
for Medical Research (London).
Induction ofAmyloid.
￿
For the imaging experiments, amyloidotic mice were produced
by daily subcutaneous injection of 0.5 ml vitamin-free casein (ICN Pharmaceuticals Inc.,
Cleveland, OH) at 10% wt/vol in 0.05 M NaHCO3 (13) five times per week for 5 wk.
Amyloid was induced in mice used for
'2'I trace labeling experiments by intravenous
injection of0.5 ml amyloid-enhancing factor (AEF), followed immediately by subcutaneous
injection of 0.5 ml 2% wt/vol AgNO, in distilled water. The animals were studied 4 wk
afterwards. AEF was prepared by the method of Axelrad et al. (14) using the spleens of
CBA mice in which amyloidosis had been induced by repeated casein injections.
Histology.
￿
Amyloid was identified by alkaline alcohol Congo red staining (15) of 6-tcm
frozen sections and the extent of deposition was estimated semiquantitatively by deter-
mination of the proportion of the area of the sections occupied by Congophilic green
birefringent material.
RIA for Mouse AA in Tissue.
￿
AA was quantitated by RIA in standard homogenates of
spleen and liver that had been treated with formic acid to solubilize amyloid fibrils and
enhance their antigenic reactivity. The RIA (Hawkins, P. N., and M. B. Pepys, manuscript
in preparation) involved absorption ofa fixed dose ofrabbit anti-AA antibodies (produced
by immunization with acute-phase mouse HDL [16]) by the tissue AA. Residual anti-AA
activity was then measured in a microtiter plate solid-phase system with degraded AA
amyloid (17) coated on the wells and '2'I-labeled immunopurified goat anti-rabbit IgG
antibody for detection of bound anti-AA. The assay was standardized using dilutions of a
homogenate of a pool of very heavily amyloid-laden spleens and results are expressed as
percent equivalence to this AA-rich standard per gram of whole organ.
Proteins.
￿
Mouse SAP (18), human SAP (19), human CRP (19), and Limulus polyphemus
CRP (20) were isolated and purified as previously reported. All preparations were >99%
pure by reduced SDS-PAGE (21) with heavily overloaded gels (50-100-lAg samples) stained
with Coomassie Blue.
Iodination of Proteins.
￿
Purified proteins were iodinated by the N-bromosuccinimide
(British Drug Houses, Poole, England) method (22) and then separated from free iodide
by gel filtration on Sephadex G25 (PD10 column; Pharmacia Ltd., Milton Keynes, UK)
in PBS. For RIA of AA in tissues and trace labeling experiments with pentraxins, carrier-
free Na.
1211 (IMS 30; Amersham plc, Amersham, UK) was used. For imaging experiments,
dry Na
1211 (Atomic Energy Research Establishment, Harwell, UK) was used. After gel
filtration, >95% of the radioactivity was precipitable with 10% wt/vol TCA. Functional
integrity of labeled pentraxins was confirmed in each case by demonstrating that they
retained intact their specific ligand-binding activity for phosphoethanolamine immobilized
on carboxyhexyl Sepharose (Pharmacia Ltd.) (23).
Gamma Camera Imaging and Kinetics ofLocalization of ' 2'I-SAP.
￿
Human SAP: groups
of six mice, three with casein-induced amyloid and three controls maintained under
otherwise identical conditions, were injected intravenously with 550,uCi '2'I-human SAP
(sp act, 5.5 kCi/,ug) at time 0 and were scanned at 0.5, 2, 4, 19, and 24 h thereafter with
a Toshiba gamma camera and pinhole collimator, for periods of 1-4 min under ether
anesthesia. The mice were then bled out and killed. The TCA-precipitable cpm/g of
blood were determined and the spleens, livers, and kidneys were removed and counted
in a gamma counter. The organs were then snap frozen for histological processing.
Mouse SAP: the same procedure was performed using 550 ACi "'I-mouse SAP (sp act,
5.5 uCi/,ug) except that the scans were performed at 0, 0.5, 3, 5, and 24 h. All counts
were corrected for isotope decay.
Organ Localization of '2'I-Labeled Proteins.
￿
Four groups of 10 mice, five with AEF-
induced amyloid and five controls, were injected intravenously with the following radio-
labeled proteins respectively: '2sI-mouse SAP, 1211-human SAP, "'I-human CRP, and '2'I-
Limulus CRP. Each mouse received 0.6 UCi of 12'1-protein at time 0. The specific activity
of each protein was 0.4,Ci/,ug. At 24 h the mice were bled out, and their spleens, livers,
and kidneys were removed, weighed, and counted in a gamma counter. A portion ofeach100
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FIGURE 1 .
￿
Whole body clearance of "I-SAP in amyloidotic (/)
and control ([I) mice . Each point represents themeantSD ofthree
animals. (A) Human SAP; the difference between groups was sig-
nificant at 4 h (P < 0.01) and at 24 h (P< 0.001) . (B) Mouse SAP;
the difference between groups was significant at 5 h (P < 0.05) and
at 24h(P<0.01).
organwas then snap frozen for histological examination, the remainder stored at -20°C,
and subsequently assayed for the presence ofAA protein by RIA .
Statistical Analysis .
￿
Histological and RIA estimates of amyloid in each organ were
tested for significant correlation using Spearman's rank correlation coefficient (R) . Cor-
relations between localization of SAP and these estimates of amyloid quantity were also
tested in the same way . Statistical significance of differences in whole body clearance and
organ distribution of labeled SAP was sought using Student's t tests .
Results
Gamma Camera Imaging after Injection of 12'1-Human SAP.
￿
After intravenous
injection of "I-human SAP into normal, control mice, gamma camera images
showed the presence of activity compatible with its distribution in the blood
pool . There was rapid whole body clearance so that only 65% of injected counts
remained after 4 h and25% or less at 24 h (Fig . 1A) . Over this period there was
some uptake of activity into the thyroid glands, which were not blocked before-
hand, and minor retention of iodinated material in the upper abdomen and the
bladders ofsome animals . Control mice killed at 24 hhadasignificant proportion
of the total body counts in their stomachs, presumably as a result of swallowing
excreted material during grooming, combined with gastrointestinal stasis due to
repeated ether anesthesia . There was no evidence of any significant localization
of activity elsewhere in the control animals (Fig . 2) .
In contrast, mice that had received repeated casein injections, and that all had
amyloidosis, yielded distinctly different images within 30 min of injection of
1211_
human SAP. There was major, specific localization of activity in their spleens
andlivers (Fig. 2), no localization elsewhere, and significant whole body retention
of counts compared with the controls (Fig . 1A) . These results were confirmed
by the counts detected in the individual organs removed 24 h after injection
(Fig . 3), corresponding exactly with the presence of amyloid in histological
sections . None of the control animals contained any amyloid, whereas the casein-
injected mice all had similar, massive amyloid deposits in their spleens and
definite widespread, although less extensive, deposits in their livers . There wereFIGURE 2 .
￿
Scintigrams of mice after intravenous injection of 12'I-human SAP . (Top) Serial
images of a single casein-induced amyloidotic animal in a ventral projection taken at time 0
after injection (left), 0.5 h (center), and 19 h (right), showing initial distribution in the blood
pool followed by rapid sequestration and retention in the amyloid-laden liver and spleen with
complete clearance elsewhere . (Bottom) Composite image of four mice 24 h after injection .
Controls on left top and bottom ; casein-induced amyloid mice right top and bottom . The
latter show massive localization to the liver and spleen with traces of activity in the thyroid ;
the controls show thyroid activity only, with even less elsewhere .HAWKINS ET AL .
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1 of five mice. H, human; L, Limulus ; M, mouse .
only minute traces of amyloid in the kidneys ofsome of the test mice and none
was found elsewhere .
Gamma Camera Imaging after Injection of' 2rl-Mouse SAP.
￿
Injection of labeled
mouse SAP gave results similar to those seen with human SAP except that the
proportion of the dose localized to amyloidotic organs was smaller (Fig . 3) .
Furthermore, there was more rapid clearance of organ-localized activity than
occurred with labeled human SAP. Finally, whole body retention of ' 23I-mouse
SAP was more prolonged than that ofhuman SAP and therewas little difference
between amyloid and control mice (Fig . 1 B), as we have reported previously for
"5I-mouse SAP (24) . As a result, the production of gamma camera images at 24
h took longer, the blood background was higher, and contrast was slightly less
good .
Localization of ' 257-Pentraxins in AEF-induced Amyloid .
￿
All the animals that
received AEF and silver nitrate became amyloidotic, but there was generally
much less amyloid present than in casein-injected animals as well as much greater
variation between individuals . The quantity of amyloid present in each organ at
the end of each experiment was estimated independently by histology and by
RIA for tissue AA . The results correlated in general, though by no means
absolutely : livers, Spearman's rank correlation coefficient r = 0.421, n = 20,p
< 0.05; spleens, r= 0.478, n= 20,p< 0.05. Theseresults reflect theconsiderable
difficulty in obtaining reliable, quantitative estimates of the amount of amyloid
in affected tissues.
However, the specificity of deposition of injected SAP in amyloid deposits was
confirmed using 125I-trace-labeledhumanandmouse SAP,compared withhuman
and Limulus CRP as controls . The CRP molecules closely resemble their SAP
counterparts in terms of structure but differ with respect to their calcium-
dependent ligand-binding specificity . Both human and mouse ` 25I-SAP showed
highly significant specific uptake into amyloidotic compared with normal, control
livers and spleens, and the proportions of the injected doses that localized were
similar to those seen in the imaging experiments (Fig . 4) . Labeled human CRP
showed significantly greater uptake into amyloidotic than normal organs, but
the quantities involved were extremely small; e.g., the amount in the spleen was908
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TABLE I
Quantitation of Tissue Amyloid Deposits
Histological score (median [range])expressed aspercent area ofmicroscope fieldsscanned containing green birefringent amyloid; RIA results
are AA content/g of tissue (median [range]) expressed as percent ofstandard AA-rich spleen (see Materialsand Methods) ; 1151-protein localized
at 24 h expressed as percentof injected dose/g of liveror spleen (mean t SD). Five mice in each group.
^"10% of that of mouse SAP and 2.5% of human SAP . Limulus CRP did not
show any such localization at all .
Despite the qualitative specificity of deposition of labeled SAP in amyloidotic
organs (Fig. 4, Table 1), therewas relatively poor correlationbetween the amount
of label present and the estimates of amyloid either by histology or RIA . Thus,
only the following correlation coefficients were significant (P < 0.05) : RIA vs .
human SAP and histology vs . human SAP in the liver, and histology vs. mouse
SAP in the liver and histology vs . mouse SAP in the spleen . However, if the
control mice, in which there was no amyloid by either test and no SAP localiza-
tion, were included, the correlations became highly significant (P < 0.001) in all
comparisons .
The lack of precise correlation between counts localized and estimates of
"severity" of amyloid in the amyloidotic animals may reflect, once again, the
difficulty in estimating amounts of amyloid present, but could also result from
variation between animals in the availability, in its broadest sense, ofamyloid for
binding by SAP . There was also some evidence of differences between amyloid
deposits in different organs with respect to their capacity to take up labeled SAP .
Thus, much more labeled SAP localized per gram of tissue in the spleen than in
the liver (Table I) and the ratio of these values generally exceeded the ratio of
estimated quantities of amyloid in the respective organs .
Discussion
The present results demonstrate that
129I-labeled SAP can be used to provide
specific high resolution gamma camera images of tissue amyloid deposits in vivo .
A remarkable proportion of the injected dose ofSAP localizes in organs contain-
ing amyloid . After 24 h, this was ^"10% with mouse SAP and an extraordinary
40% with human SAP, after injection of 100 ug of protein in each case . These
values compare with typical results of <1% of the injected dose of monoclonal
antitumor antibodies that localize specifically to neoplastic lesions in man or
animals (25) . Human SAP that had localized to amyloid deposits was retained
there with little loss between 4 and 24 h after injection, in contrast to its rapid
and extensive whole body clearance in control mice . The whole body clearance
ofmouse SAP was slower than that ofhuman SAP but was similar in amyloidotic
1151-Protein Pretreatment
Histology
Liver
RIA 1151-Protein Histology
Spleen
RIA 115 1-Protein
Human SAP AEF/AgNO 3 1 .5 (0.5-5 .0) 4.5(1-19) 21 .6 t 9.4 4.8 (2.5-10) 35(7.1-57) 227 .2 t 66 .0
Human SAP - 0 0 0 .4 ± 0.1 0 0 0 .8 ± 0.8
Mouse SAP AEF/AgNO, 5.0(1-10) 12 .0 (4.7-55) 4 .6 t 1 .5 22.0 (10-40) 28(22-188) 59 .1 t 29 .4
Mouse SAP - 0 0 1 .8 ± 0.2 0 0 5 .9 ± 8.4
Human CRP AEF/AgNO3 3.9(0 .5-5) 17.0(5-23) 1 .9 t 1 .2 10.0(4-20) 65(20-402) 6 .1 t 5 .9
Human CRP - 0 0 0.9 ± 0 .1 0 0 0 .7 ± 0.5
Limultu CRP AEF/AgNOs 2.7(0.5-5) 95 .0 (19-50) 0.6 t 0 .0 5.0(1-25) 60(20-105) 0 .6 t 0 .2
LimulusCRP - 0 0 0.5 ± 0 .1 0 0 0 .9 ± 0 .2HAWKINS ET AL .
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and control mice . Together with the smaller proportion of the injected dose that
localized to amyloid, this suggests thatmouse SAP has a lower affinity for binding
to isologous AA fibrils than does the heterologous protein, human SAP . This is
a novel and interesting finding that merits further investigation especially in the
light of the high resolution three-dimensional structure of human SAP which
will soon become available (26, 27) . However, in purely operational terms, it
means that human SAP is a better targeting agent for mouse AA amyloid than
is mouse SAP .
Of the control proteins studied, Limulus CRP did not localize at all to amyloid
deposits, while human CRP showed significant localization but only at a trace
level . This is not surprising since human CRP and SAP show a slight overlap in
ligand-binding specificity (23, 28, 29), and we have reported previously that this
may extend to the ligand(s) on human amyloid since CRP showed weak binding
to two of three different AL fibril preparations (21) . In further experiments, not
shown here, we have investigated the in vivo localization to mouse AA amyloid
deposits of the two distinct bovine pentraxins that we recently characterized for
the first time (30) . Both localized to amyloid, one as well as human SAP, and the
other less well, but still appreciably better than mouse SAP . There is thus scope
for further study of heterologous pentraxins in this experimental system and
possibly also in a clinical context in the future .
In a previous, preliminary report, we established that low resolution, but
nonetheless, diagnostic images ofmurine amyloid could be obtained in vivo after
injection of 'g'I-human SAP (31) . The superior, high resolution results shown
here reflect the excellent properties of 1231 with its high energy (0.159 MeV) y
emission and high photon yield in the gamma camera. Other advantages, partic-
ularly for prospective clinical applications, are the low ,B emission, the short half-
life (13 h), and the ease of efficient protein labeling . Unfortunately, however,
"'I is available only from a limited number of centers . More widely available
isotopes suitable for scintigraphy are 99mTc and "'In, but the former is not
readily conjugated with native proteins, and after injection of proteins labeled
with "' In there is marked nonspecific uptake of isotope in the liver . This is well
known in man (32) and we have encountered the same problem in mice with
"'In-SAP labeled by the diethylenetriaminepentaacetic acid method (unpub-
lished observations) .
The qualitative specificity of localization of injected SAP to amyloid has been
well established here, but a major question remaining is whether the quantity of
SAP that localizes reflects the absolute amount of amyloid present . This question
is difficult to answer precisely because of the problems involved in accurate
estimation of the amyloid content of tissues . Histological examination of Congo
red-stained sections cannot reasonably sample more than a very small proportion
of the liver or spleen, and even then light microscopic evaluation of green
birefringent areas may not reflect quantitatively the absolute amount of amyloid
fibril deposits . Nevertheless, in mice with casein-induced amyloid, which all had
similar and extensive Congophilic, green birefringent deposits in their spleens
and livers, there was very little variation in the proportion of the injected dose
of labeled SAP that localized . On the other hand, in the AEF-induced model
there was much less amyloid in the tissues assessed histologically, and much91 0
￿
IN VIVO IMAGING OF AMYLOID DEPOSITS
greater variation between mice than in the casein-induced model. While in these
mice the absolute specificity of SAP for amyloidotic organs was retained, there
were only imperfect correlations between labeled SAP localized and histological
score.
Our RIA for tissue AA was intended to overcome the sampling and interpre-
tation problems of histology. It was highly specific and gave no false-positive
results but showed only partial correlation with Congo red staining and with
quantity of SAP localized. Given the complexity of amyloid deposits, including
fibrils of different ages, glycosaminoglycans, and SAP, there is no a priori reason
to expect that there should necessarily be a close correlation between Congo red
birefringence (the precise molecular basis of which is not known), AA antigen
content, and SAP deposition. Indeed we observed here that appreciably more
SAP seemed to localize in the spleen than in the liver in association with
apparently similar quantities of amyloid.
It is possible, therefore, that these variable correlations seen with AEF-induced
amyloid and trace- "'I-labeled SAP were due to inherent features of amyloid
pathology, rather than merely the operational problems of amyloid quantitation.
For example, the ligand on amyloid fibrils to which SAP binds has not yet been
biochemically identified; it is not known whether it is exposed on all fibrils at all
times during the pathogenesis of fibril deposition, nor whether competitive
ligands exist either in body fluids or on other tissue components. Another
potentially important variable is local vascular permeability, which may deter-
mine when, where, and how much SAP (M,. 254,000 [reference 27]) leaves the
circulation to enter amyloidotic tissue. It will be important, therefore, to deter-
mine whether or not SAP localizes with the same kinetics and to the same extent
in relation to similar amounts of amyloid fibrils in different tissue sites and at
different stages of the disease. Regardless of the outcome of such studies, we
have here demonstrated for the first time a noninvasive procedure for specific
in vivo imaging of amyloid that is potentially applicable in man, and studies in
patients with various forms of amyloid are currently in progress. Diagnostic
imaging methods based on the presence of abundant calcium in amyloid deposits
(33) have previously been used clinically, but they are not specific and have
limited sensitivity (34, 35) . Imaging of AA amyloid in mice has been achieved
with radiolabeled monoclonal anti-AA antibodies (36), but this is clearly not an
approach that could be generally applicable in man, given the diversity ofamyloid
fibril proteins and the problems posed by injection of heterologous Igs.
Availability of a repeatable in vivo diagnostic procedure should increase
knowledge of the natural history of amyloid and may ultimately permit early
diagnosis in groups at risk, such as chronic haemodialysis, rheumatoid arthritis,
and juvenile chronic arthritis patients. Another possible application is in Alz-
heimer's disease and senile dementia of Alzheimer type, presently diagnoses of
exclusion, but in which cerebrovascular amyloid containing SAP is almost uni-
versally present (7, 37-40). Finally, the present successful demonstration of
specific localization to amyloid of intravenously injected radiolabeled SAP sug-
gests that SAP could also be used as a targeting vehicle to transport to amyloid
deposits substances with potentially beneficial therapeutic effects. Experiments
to test this concept are in progress.Highly specific, high-resolution scintigraphic images of amyloid-laden organs
in mice with experimentally induced amyloid A protein (AA) amyloidosis were
obtained after intravenous injection of ' 23I-labeled serum amyloidP component
(SAP). Interestingly, amuch higher proportion (up to 40%) of the injected dose
of heterologous human SAP localized to amyloid and was retained there than
was the case with isologous mouse SAP, indicating that human SAP binds more
avidly to mouse AA fibrils than does mouseSAP. Specificity of SAP localization
was established by the failure of the related proteins, human Greactive protein
and Limulus Greactive protein, to deposit significantly in amyloid and by the
absence of human SAP deposition in nonamyloidotic organs . However, only
partial correlations were observed between the quantity of SAP localized and
two independent estimates, histology and RIA forAA of the amount of amyloid
in particular organs . It is not clear which of the three methods used reflects
better the extent or clinical significance of the amyloid deposits but in vivo
localization of radiolabeled SAP, detectable and quantifiable by gamma camera
imaging, is apparently extremely sensitive . These findings establish the use of
labeled SAP as a noninvasive in vivo diagnostic probe in experimental amyloi-
dosis, potentially capable of revealing the natural history of the condition, and
suggest that it may also be applicable generally as a specific targeting agent for
diagnostic and even therapeutic purposes in clinical amyloidosis .
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